M2 PHARMA-March 16, 2018-ImmunoRestoration Licenses Immunotherapeutic
Cancer Vaccine Platform from the University of Pennsylvania
Many of Lius discoveries are being translated into immunotherapeutic
approaches for cancer and autoimmune diseases, with a first-in-class immunotherapeutic
now in a phase II clinical trial.
2m Financing for Gene Regulatory and Immunotherapeutic
This new research is going to revolutionize the mechanism of action of immunotherapeutic
drugs, thus creating wide range of opportunities for innovation and development in this field.
GlaxoSmithKline plc today announced its decision to stop the MAGRIT trial, a Phase III trial of its MAGE-A3 cancer immunotherapeutic
in non-small cell lung cancer (NSCLC) patients, after establishing that it will not be possible to identify a sub-population of gene-signature positive NSCLC patients that may benefit from the treatment.
They address new principles of immune suppression in cancer and recent thinking in how immunotherapeutic
and chemotherapeutic agents might be combined to defeat mechanisms of tumoral immune suppression and reprogram the inflammatory microenvironment of tumor cells to enhance long-term outcomes.
By utilizing an individual's disease antigens to create a personalized immunotherapeutic
, the broadest possible immune response can be realized to maximize anti-disease activity, and these so-called immunotherapeutics
have the potential as a multi-billion dollar market.
An improved Pythium insidiosum-vaccine formulation with enhanced immunotherapeutic
properties in horses and dogs with pythiosis.
The primary study objective is to evaluate patient-specific anti-viral response to the AGS-004 immunotherapeutic
following four doses over four weeks.
Science and technology company Leidos (NYSE:LDOS) stated on Monday that it plans to create a new business relationship for identifying and advancing immuno-oncology and other immunotherapeutic
opportunities via the terms of a Memorandum of Understanding (MOU) with Biosortia Pharmaceuticals.
MAGRIT, a randomised, double-blind, placebo-controlled trial, is evaluating the efficacy and safety of the MAGE-A3 cancer immunotherapeutic
in Stage IB, II and IIIA completely resected NSCLC patients whose tumours expressed the MAGE-A3 gene.
The primary objective of the trial is to measure patient-specific anti-tumor response of the AGS-005 immunotherapeutic
following treatment with one low dose of intravenous cyclophosphamide.